Skip to main content

Table 2 Outcome Ascertainment for INSIGHT

From: The rationale and design of Insight into Nephrotic Syndrome: Investigating Genes, Health and Therapeutics (INSIGHT): a prospective cohort study of childhood nephrotic syndrome

 

Follow up time since initial onset (months)

 

4

8

12

24

36

48

60

Clinical

       

Remission: Urine protein/creatinine < 0.2 or Albustik negative or trace for 3 consecutive days

x

x

x

x

x

x

x

Relapse: After remission, an increase in the first morning urine protein/creatinine ≥2 for 3 of 5 consecutive days

x

x

x

x

x

x

x

Frequently relapsing NS: 4 or more relapses within 1 year OR 2 or more relapses within 6 months

  

x

x

x

x

x

Steroid dependant NS: Relapse during steroid taper or within 14 days of steroid discontinuation

x

x

x

x

x

x

x

Steroid resistant: Inability to induce remission within 28 days of steroid therapy

x

x

x

x

x

  

Laboratory

       

Urine protein/creatinine: Abnormal if > 250 mg/mmol

x

x

x

x

x

x

x

Urine albumin/creatinine: Abnormal if > 30 mg/mol

x

x

x

x

x

x

x

Creatinine based eGFR: eGFR by modified Schwartz (ml/min/1.73 m2) = k x height/serum creatinine

x

x

x

x

x

x

x

CKD/ESRD: eGFR < 60 ml/min/1.73 m2 (or dialysis)

   

Anytime

  Â